

Tyrolian algae extract with anti-inflammatory potential


algae extract, ointment, skin, natural product, photo-protective, anti-inflammatory, phyto-pharmaceutic and cosmetic composition

INVENTION NOVELTY

Glucocorticoids are used in the treatment of various skin conditions and diseases which cause damaging inflammatory reactions. While representing a cornerstone in dermatologic therapy through their beneficial effects in reducing inflammation, they show adverse effects especially in children and individuals with sensitive skin (e.g. acne, skin atrophy, rosacea, perioral dermatitis). Surprisingly, extracts obtained from soil algae from the alps, showed strong anti-inflammatory properties. Such extracts can be used in the prophylaxis and treatment of inflammations or inflammatory diseases, especially of the skin, without any major side effects seen with glucocorticoids.

VALUE PROPOSITION

The invention comprises an anti-inflammatory extract of alpine soil algae (Chlorophyta or Xanthophyceae) or a fraction thereof. Alpine soil algae are of special interest for the production of secondary metabolites with photo-protective and anti-inflammatory properties due to their exposure to extreme environmental conditions including high levels of UV radiation. Such extract or fraction thereof may be beneficial in pharmaceutical compositions as well as cosmetic compositions and food or drink supplements.



Algae collection (source:
Prof. Huber, MUI)

TECHNOLOGY DESCRIPTION

Algae strains from a unique algae collection were screened for their potential to produce metabolites with anti-inflammatory activities. The inflammatory response has been induced in a newly generated NF- κ B reporter cell line (human keratinocyte HaCaT) and treated with selected soil algae extracts. Several extracts had a pronounced inhibitory effect on the reporter activity. Validation was carried out using dose response experiments to verify the dose dependency of soil algae metabolites.

Extract originating from the algae strain *Chromochloris zofingiensis* cultivated under the specifically administered stress condition was generated. The extract was not cytotoxic as shown by LDH-release and Resazurin assays while significantly reducing the release of various pro-inflammatory cytokines in human epidermis equivalents. A bioactivity guided fractionation was performed and only fraction N8 showed inhibition of NF- κ B activation. Mass spectrometry analysis identified 5 leading metabolites in fraction N8: Diacylglycerol-N,N,N-trimethylhomo-Serine (DGTS), Lyso-DGTS, p-coumaric acid, Oleamide and Theophyllin.

COMMERCIAL OPPORTUNITY

The algae extract or fraction offer a valuable product opportunity as anti-inflammatory ointment for topical application, but also usable as capsule or tablet in a systemic application. The technology is open for licensing, further pre-clinical and clinical co-development is highly welcomed.

DEVELOPMENT STATUS

Fraction N8 is the most potent unit regarding an anti-inflammatory effect. Treatment with extract or fraction N8 revealed the inhibition of TNF α -induced I κ B α degradation and ERK1/2 phosphorylation and activation of NF- κ B downstream of TAK1 thus interfering directly with the IKK complex activity. It can be developed as a phytotherapeutic to treat skin diseases and other inflammatory disorders.

PATENT SITUATION

Patents are pending in US and EP with priority of June 18, 2021.

FURTHER READING

Leitner et al. (2022), Cells 11:1407



Ascenion GmbH
Herzogstraße 64
D-80803 München
info@ascenion.de
www.ascenion.de

Licensing Contact
Dr. Hubert Müller
Technology Manager
T: +49 89 318814-32
mueller@ascenion.de

